JP2002512261A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002512261A5 JP2002512261A5 JP2000545211A JP2000545211A JP2002512261A5 JP 2002512261 A5 JP2002512261 A5 JP 2002512261A5 JP 2000545211 A JP2000545211 A JP 2000545211A JP 2000545211 A JP2000545211 A JP 2000545211A JP 2002512261 A5 JP2002512261 A5 JP 2002512261A5
- Authority
- JP
- Japan
- Prior art keywords
- hiv
- component
- molecule
- radioimmunoconjugate
- epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010041397 CD4 Antigens Proteins 0.000 description 2
- 102100013077 CD4 Human genes 0.000 description 1
- 208000005721 HIV Infections Diseases 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
Description
【特許請求の範囲】
【請求項１】 免疫学的に作用する成分として、唯一のタンパク質成分として、ＨＩＶ−１および／またはＨＩＶ−２の表面グリコプロテインｇｐ１２０におけるエピトープへの親和性を有するＣＤ４レセプター分子またはＣＤ４分子のフラグメントと、
放射性成分として、１３１Ｉ、３２Ｐ、９０Ｙ、８９Ｓｒのような治療目的に適した放射性核種と
を含むことを特徴とする放射性免疫複合体。
[Claims]
1. A CD4 receptor molecule or a fragment of a CD4 molecule which has an affinity for an epitope on the surface glycoprotein gp120 of HIV-1 and / or HIV-2 as the sole protein component as an immunologically active component. When,
A radioimmunoconjugate comprising a radionuclide suitable for therapeutic purposes such as 131 I, 32 P, 90 Y, 89 Sr as a radioactive component.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1998126307 DE19826307A1 (en) | 1998-03-08 | 1998-04-15 | CD4 radio immunological pharmaceuticals |
| DE19826307.4 | 1998-04-15 | ||
| PCT/DE1999/001177 WO1999054954A2 (en) | 1998-04-15 | 1999-04-15 | Cd4 radio-immunological pharmaceuticals for the treatment of hiv infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002512261A JP2002512261A (en) | 2002-04-23 |
| JP2002512261A5 true JP2002512261A5 (en) | 2006-06-15 |
Family
ID=7870747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000545211A Pending JP2002512261A (en) | 1998-04-15 | 1999-04-15 | CD4 radioimmune drug for treating HIV infection |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1071475A2 (en) |
| JP (1) | JP2002512261A (en) |
| AU (1) | AU4497199A (en) |
| DE (1) | DE19980721D2 (en) |
| WO (1) | WO1999054954A2 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991004050A1 (en) * | 1989-09-14 | 1991-04-04 | Board Of Regents, The University Of Texas System | Therapeutic compositions; methods for treatment of hiv infections |
| CA2049964A1 (en) * | 1990-01-26 | 1991-07-27 | Mark P. Pasek | C4 binding protein fusion proteins |
| GB9217124D0 (en) * | 1992-08-13 | 1992-09-23 | Antisoma Ltd | Medical treatment |
| WO1997003198A2 (en) * | 1995-07-07 | 1997-01-30 | Texas A & M University System | Nucleotide and amino acid sequence and uses thereof |
| DE19809785C2 (en) * | 1998-03-08 | 2000-02-10 | Wolfgang Bergter | Radioimmune drug for the treatment of HIV-1 infection |
-
1999
- 1999-04-15 EP EP99927685A patent/EP1071475A2/en not_active Withdrawn
- 1999-04-15 AU AU44971/99A patent/AU4497199A/en not_active Abandoned
- 1999-04-15 WO PCT/DE1999/001177 patent/WO1999054954A2/en not_active Application Discontinuation
- 1999-04-15 DE DE19980721T patent/DE19980721D2/en not_active Ceased
- 1999-04-15 JP JP2000545211A patent/JP2002512261A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200000329A (en) | Oral Form For Acid-Unstable Active Ingredients, Method Of Preparation And Use Of A Unit Of Acid-Unstable Active Ingredient | |
| TR200001544T2 (en) | New compounds. | |
| ATE486840T1 (en) | MODIFIED FORMS OF PHARMACEUTICALLY ACTIVE AGENTS AND USES THEREOF | |
| JP2002506648A5 (en) | ||
| DK1036058T3 (en) | adamantane | |
| DK1036059T3 (en) | adamantane | |
| JP2002511411A5 (en) | ||
| CA2082948A1 (en) | Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding | |
| IT8220781A0 (en) | PHARMACOLOGICALLY ACTIVE BIPHOSPHONATES, PROCEDURE FOR THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS. | |
| EP1178786A4 (en) | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof | |
| HUP0202537A2 (en) | A vaccine composition and method of using the same | |
| ATE252377T1 (en) | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING TILIDINE MESYLATE AS THE ACTIVE INGREDIENT | |
| HUP9900154A2 (en) | Trovafloxacin mesilate tablet | |
| HK1064936A1 (en) | Use of polyclonal anti-hiv goat serum as a therapeutic agent | |
| WO2002067865A3 (en) | N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof | |
| WO1991015512A3 (en) | Hiv envelope polypeptides | |
| DE60141297D1 (en) | AGAINST THE HUMAN BST2 ANTIGEN-TUNED MONOCLONAL ANTIBODY | |
| NO984540D0 (en) | Cytochrome P450 transducing retroviral vectors | |
| ATE187890T1 (en) | LIGAND DIRECTED ENZYME PRODRUG THERAPY | |
| JP2002512261A5 (en) | ||
| DK0815141T3 (en) | Antibody to a fusion polypeptide comprising a histidine moiety | |
| DE69426021D1 (en) | Xamonelin tartrate | |
| ATE219665T1 (en) | DOSAGE FORMS AND USES THEREOF | |
| NO166642C (en) | ANAOLOGICAL PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 3-ARYL-5-ALKYLTHIO-4H-1,2,4-TRIAZOLES. | |
| JP2002519334A5 (en) |